Metabolic Effects of Antipsychotic Substitution in Children.

Trial Profile

Metabolic Effects of Antipsychotic Substitution in Children.

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 08 May 2014

At a glance

  • Drugs Aripiprazole; Olanzapine; Risperidone
  • Indications Affective disorders; Anxiety disorders; Asperger syndrome; Attention deficit and disruptive behaviour disorders; Autistic disorder; Bipolar disorders; Conduct disorder; Depressive disorders; Generalised anxiety disorder; Gilles de la Tourette's syndrome; Major depressive disorder; Mood disorders; Movement disorders; Obsessive-compulsive disorders; Pervasive child development disorders; Psychotic disorders; Schizophrenia; Social phobia; Tic disorders
  • Focus Adverse reactions
  • Acronyms SMEAC
  • Most Recent Events

    • 20 Nov 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov
    • 06 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top